Atea Pharmaceuticals, Inc. - COMMON STOCK (AVIR) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2020 to Q4 2025

Type / Class
Equity / COMMON STOCK
Symbol
AVIR on Nasdaq
Shares outstanding
78,411,033
Price per share
$3.57
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
53,140,827
Total reported value
$154,099,214
% of total 13F portfolios
0%
Share change
+445,216
Value change
+$874,811
Number of holders
111
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Atea Pharmaceuticals, Inc. - COMMON STOCK (AVIR) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 12% +70% $29,470,003 +$10,937,987 9,095,680 +59% FMR LLC 28 Nov 2025
Sommadossi Jean-Pierre 10% $26,185,536 8,876,453 Jean-Pierre Sommadossi 31 Mar 2025
BML Investment Partners, L.P. 8.5% $21,288,120 7,216,312 Leonard Braden Michael 13 Dec 2024
BlackRock, Inc. 7.1% $17,942,932 6,082,350 BlackRock, Inc. 31 Mar 2025
Radoff Bradley Louis 4% +10% $9,971,295 +$811,250 3,380,100 +8.9% Radoff Bradley Louis 16 Apr 2025
EcoR1 Capital, LLC 4% $9,857,876 3,341,653 EcoR1 Capital, LLC 31 Dec 2024

As of 30 Sep 2025, 111 institutional investors reported holding 53,140,827 shares of Atea Pharmaceuticals, Inc. - COMMON STOCK (AVIR). This represents 68% of the company’s total 78,411,033 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Atea Pharmaceuticals, Inc. - COMMON STOCK (AVIR) together control 61% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 11% 8,459,220 -2.4% 0% $24,531,739
BML Capital Management, LLC 9.5% 7,473,963 -1.8% 20% $21,674,493
FMR LLC 7.4% 5,822,773 +1.8% 0% $16,886,041
TANG CAPITAL MANAGEMENT LLC 6.2% 4,826,200 -1.3% 0.54% $13,995,980
VANGUARD GROUP INC 6% 4,709,275 -3.6% 0% $13,656,897
Bain Capital Life Sciences Investors, LLC 3.2% 2,485,638 0% 0.48% $7,208,350
GEODE CAPITAL MANAGEMENT, LLC 2.4% 1,899,737 -1.3% 0% $5,510,507
STATE STREET CORP 2.3% 1,783,976 +0.43% 0% $5,173,530
DIMENSIONAL FUND ADVISORS LP 2% 1,540,716 +9.2% 0% $4,468,201
RENAISSANCE TECHNOLOGIES LLC 1.6% 1,227,900 -0.5% 0% $3,560,910
ACADIAN ASSET MANAGEMENT LLC 1.2% 969,773 +5.7% 0% $2,810,000
TWO SIGMA ADVISERS, LP 1% 796,200 +14% 0% $2,308,980
NORTHERN TRUST CORP 0.81% 638,388 -5.5% 0% $1,851,325
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.8% 624,984 -1.6% 0% $1,812,454
JPMORGAN CHASE & CO 0.79% 616,851 -5.5% 0% $1,788,869
CM Management, LLC 0.64% 500,000 0% 1.2% $1,450,000
Newtyn Management, LLC 0.63% 492,284 -15% 0.17% $1,427,624
MILLENNIUM MANAGEMENT LLC 0.62% 487,223 +179% 0% $1,412,947
TWO SIGMA INVESTMENTS, LP 0.6% 471,293 +29% 0% $1,366,750
Peapod Lane Capital LLC 0.58% 457,216 +1% 1.2% $1,325,921
MORGAN STANLEY 0.57% 450,564 -17% 0% $1,306,636
JACOBS LEVY EQUITY MANAGEMENT, INC 0.51% 398,423 +37% 0% $1,155,427
D. E. Shaw & Co., Inc. 0.47% 364,768 +86% 0% $1,057,827
BANQUE PICTET & CIE SA 0.44% 345,077 0% 0.01% $1,000,723
GOLDMAN SACHS GROUP INC 0.43% 340,140 +14% 0% $986,406

Institutional Holders of Atea Pharmaceuticals, Inc. - COMMON STOCK (AVIR) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 571,125 $2,037,717 -$34,381 $3.57 7
2025 Q3 53,140,827 $154,099,214 +$874,811 $2.90 111
2025 Q2 52,688,325 $189,687,193 -$496,611 $3.60 105
2025 Q1 52,943,893 $158,295,789 -$11,408,006 $2.99 102
2024 Q4 56,328,149 $188,651,399 -$6,772,701 $3.35 103
2024 Q3 57,907,511 $193,998,567 +$4,533,749 $3.35 105
2024 Q2 56,687,549 $187,637,646 +$7,123,002 $3.31 101
2024 Q1 54,332,807 $219,504,800 -$1,664,806 $4.04 112
2023 Q4 55,088,379 $168,248,591 -$1,691,841 $3.05 106
2023 Q3 56,849,245 $170,555,234 -$2,209,314 $3.00 117
2023 Q2 57,041,241 $213,289,848 +$971,494 $3.74 131
2023 Q1 56,778,720 $190,176,002 -$5,878,803 $3.35 128
2022 Q4 57,878,556 $278,395,526 -$5,016,357 $4.81 130
2022 Q3 57,466,718 $326,999,436 -$1,731,457 $5.69 115
2022 Q2 57,566,762 $408,727,109 +$19,469,875 $7.10 122
2022 Q1 54,946,542 $396,539,427 +$6,369,699 $7.22 121
2021 Q4 53,581,427 $478,985,081 -$368,375,568 $8.94 134
2021 Q3 56,840,788 $1,992,582,650 -$21,707,203 $35.06 137
2021 Q2 58,896,806 $1,265,508,812 +$160,923,836 $21.48 100
2021 Q1 47,389,412 $2,914,493,173 +$30,510,569 $61.75 78
2020 Q4 49,910,976 $2,070,766,859 +$1,819,869,860 $41.78 69